https://scholars.lib.ntu.edu.tw/handle/123456789/635373
標題: | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | 作者: | Döhner, Hartmut Wei, Andrew H Appelbaum, Frederick R Craddock, Charles DiNardo, Courtney D Dombret, Hervé Ebert, Benjamin L Fenaux, Pierre Godley, Lucy A Hasserjian, Robert P Larson, Richard A Levine, Ross L Miyazaki, Yasushi Niederwieser, Dietger Ossenkoppele, Gert Röllig, Christoph Sierra, Jorge Stein, Eytan M Tallman, Martin S HWEI-FANG TIEN Wang, Jianxiang Wierzbowska, Agnieszka Löwenberg, Bob |
公開日期: | 22-九月-2022 | 出版社: | Elsevier B.V. | 卷: | 140 | 期: | 12 | 起(迄)頁: | 1345 | 來源出版物: | Blood | 摘要: | The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-85135885465&doi=10.1182%2fblood.2022016867&origin=inward&txGid=6a48cd1312ebe03a76926a90134b6d95 https://scholars.lib.ntu.edu.tw/handle/123456789/635373 |
ISSN: | 00064971 | DOI: | 10.1182/blood.2022016867 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。